BIMU RISAL BHANDARY: Open Payments
NPI 1821686718 · FAIRFAX, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,142 in 32 payments from 14 companies in 2025. Trend: 2023 $1,456 · 2024 $1,019 · 2025 $1,142
Food & beverage: $1,142
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $291 |
| AstraZeneca Pharmaceuticals LP | 3 | $147 |
| Amgen Inc. | 1 | $122 |
| Gilead Sciences, Inc. | 1 | $122 |
| Merck Sharp & Dohme LLC | 4 | $93 |
| PFIZER INC. | 4 | $90 |
| E.R. Squibb & Sons, L.L.C. | 3 | $63 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $63 |
| BridgeBio Pharma, Inc. | 2 | $46 |
| Boston Scientific Corporation | 1 | $31 |
Products named: Wegovy, TEZSPIRE, Yeztugo, REPATHA, VERQUVO, ELIQUIS, JARDIANCE, Attruby.
Industry payments across VA — which companies pay providers there.
